Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/17195
Title: Neurocognitive and behavioural performance of healthy volunteers receiving an increasing analgesic-range infusion of ketamine.
Authors: Hayley, Amie;Green, Maja;Downey, Luke A;Keane, Michael;Kostakis, Panagiota;Shehabi, Yahya
Affiliation: Centre for Human Psychopharmacology, Faculty of Health, Arts and Design, Swinburne University of Technology, Hawthorn, Victoria, 3122, Australia
Program of Critical Care and Perioperative Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia
Department of Oncology, Monash Health Translation Precinct, Monash University, Clayton, Australia
Institute for Breathing and Sleep, Austin Health, Heidelberg, Victoria, Australia
Forensic Science South Australia (FSSA), Adelaide, South Australia, Australia
Issue Date: 23-Feb-2018
EDate: 2018
Citation: Psychopharmacology 2018; online first: 23 February
Abstract: The acute and delayed effect of analgesic-range doses of ketamine on neurocognitive and behavioural outcomes is understudied. Using a non-controlled open-labelled design, three (1-h duration) increasing intravenous (IV) ketamine infusions comprising (i) 30 mg bolus of ketamine + 8 mg/h IV infusion, (ii) 12 mg/h IV infusion and (iii) 20 mg/h infusion were administered to 20 participants (15 male, 5 female, mean age = 30.8 years). Whole-blood ketamine and norketamine concentrations were determined at each treatment step and post-infusion. The Cambridge Neuropsychological Test Automated Battery (CANTAB) was used to assess reaction/movement time (RTI, Simple and 5-Choice), visuospatial working memory (SWM), spatial planning (SOC) and subjective effects (visual analogue scale; VAS) during treatment and at post-treatment. Significant main effects were reported for time (dose) on CANTAB RTI 5-Choice reaction (F(4,18) = 3.41, p = 0.029) and movement time (F(4,18) = 4.42, p = 0.011), SWM (F(4,18) = 4.19, p = 0.014) and SOC (F(4,18) = 4.13, p = 0.015), but not RTI Simple reaction or movement time. Post hoc analyses revealed dose-dependent effects for both RTI 5-Choice reaction and movement time (all p < 0.05). Post-treatment performance on all neurocognitive and behavioural tasks returned to baseline levels. Regression analyses revealed a weak positive linear association between SWM 'strategy' score (R2 = 0.103, p < 0.001), all performance-based CANTAB VAS items (R2range 0.005-0.137, all p < 0.05) and ketamine blood concentrations. The open-label, non-controlled trial design somewhat precludes the ability to adequately account for random treatment effects. Notwithstanding, these results suggest that analgesic doses of ketamine produce acute, selective, dose-dependent deficits in higher-order neurocognitive and behavioural domains.
URI: http://ahro.austin.org.au/austinjspui/handle/1/17195
DOI: 10.1007/s00213-018-4842-7
ORCID: http://orcid.org/0000-0002-4470-4718
PubMed URL: 29476241
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/29476241
Type: Journal Article
Subjects: Behavioural
Intravenous
Ketamine
Neurocognitive
Therapeutic
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.